Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Cellectis Stock Up 12.0 %

Shares of NASDAQ:CLLS traded up $0.36 during midday trading on Friday, reaching $3.35. 272,116 shares of the company were exchanged, compared to its average volume of 47,732. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.58. Cellectis has a fifty-two week low of $0.96 and a fifty-two week high of $3.77. The stock has a fifty day simple moving average of $2.60 and a two-hundred day simple moving average of $2.70. The firm has a market cap of $186.19 million, a PE ratio of -1.87 and a beta of 3.08.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.64) EPS for the quarter. The firm had revenue of $1.99 million during the quarter. Cellectis had a negative net margin of 1,087.66% and a negative return on equity of 99.88%. As a group, sell-side analysts forecast that Cellectis will post -1.06 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Principal Financial Group Inc. raised its holdings in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned 0.76% of Cellectis worth $1,125,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.